Aquestive Therapeutics Inc. logo

Aquestive Therapeutics Inc.

AQST | NASDAQ
Chart Builder DCF Calculator
$4.78
+$0.17 (+3.69%)
At close: Sep 21, 2026, 4:00 PM ET
$4.74
-$0.04 (-0.84%)
After-hours: Sep 21, 2026, 7:59 PM ET

Market Data

Market Cap
$578.4M
Enterprise Value
$560.24M
Beta
1.47
Average Volume
2.38M
Shares Outstanding (Diluted)
124.99M
Shares Change YoY
25.84%
Institutional Ownership
58.74%
Exchange
NASDAQ
ISIN
US03843E1047

Price Performance

Price Change 1M
2.4%
Price Change 3M
-5.0%
Price Change 6M
13.5%
Price Change YTD
-25.9%
Price Change 1Y
-7.5%
Price Change 3Y
202.5%
Price Change 5Y
10.4%
1M CAGR (ann.)
17.6%
1Y CAGR (ann.)
-4.5%
5Y CAGR (ann.)
0.8%
All-Time CAGR
-14.2%

Valuation

PE Ratio
-7.35
Forward PE
N/A
PEG Ratio
-6.32
Forward PEG
-3.92
PS Ratio
11.09
Forward PS
8.80
PB Ratio
-10.60
P/FCF Ratio
-13.05
P/Adj. FCF Ratio
-10.84
P/OCF Ratio
-13.28
EV/Sales
10.36
EV/EBIT
-9.05
EV/EBITDA
-9.14
EV/FCF
-12.19
Earnings Yield
-13.6%
FCF Yield
-7.7%
Adj. FCF Yield
-9.2%

Financial Health

Net Cash
$47.84M
Total Debt
$59M
Cash & Short-Term Investments
$98.49M
Total Assets
$132.1M
Current Ratio
7.19
Quick Ratio
6.74
Debt / Equity Ratio
-1.04
Debt / EBITDA
-0.96
Debt / FCF
-1.28
OCF / Debt
-0.77
Interest Coverage
-3.23
Altman Z-Score
-3.44
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
67.0%
Operating Profit Margin
-97.5%
EBITDA Margin
-113.3%
Net Profit Margin
-144.6%
FCF Margin
-85.0%
Adj. FCF Margin
-102.3%
SBC / Revenue
17.3%
SBC Impact (per share)
-20.4%

Returns

Return on Assets
-59.2%
Return on Equity
243.7%
Return on Invested Capital
-45.3%
Return on Capital Employed
-45.6%
Return on Tangible Assets
-59.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
5.2%
Revenue CAGR 5Y
5.3%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-26.5%
EPS CAGR 5Y
28.0%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-26.1%
FCF CAGR 5Y
-24.0%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
32.3%
Revenue Growth Next 3Y
51.4%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
-$0.10
EPS Growth Est (next Q)
-28.6%
Revenue Est (next Q)
$11.02M
Revenue Growth Est (next Q)
-14.0%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$11
Price Target Upside
130.1%

Cash Flow

Operating Cash Flow
$-45.37M
Free Cash Flow
$-45.95M
Adj. Free Cash Flow
$-55.32M
FCF Per Share
-$0.37
OCF Per Share
-$0.36
OCF/S Ratio
-83.9%

Income Statement

Revenue
$54.09M
Gross Profit
$36.26M
Operating Income
$-52.75M
EBITDA
$-61.27M
Net Income
$-78.23M
EPS (Diluted)
-$0.65
Revenue / Employee
$367.94K
Profit / Employee
$-532.16K
Employees
147

© 2026 bestshares.com. All rights reserved.